Journal of Clinical Oncology, Vol 16, 229-236, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma

KK Matthay, K DeSantes, B Hasegawa, J Huberty, RS Hattner, A Ablin, CP Reynolds, RC Seeger, VK Weinberg and D Price
Department of Pediatrics and the University of California, San Francisco School of Medicine, USA. katekm@itsa.ucsf.edu

PURPOSE: The analogue 131I-metaiodobenzylguanidine (MIBG), which is specifically targeted to neuroblastoma cells, may provide more effective and less toxic treatment for neuroblastoma than conventional external-beam radiotherapy. We report a dose escalation study of 131I- MIBG to define dose-limiting toxicity without and with autologous bone marrow support. PATIENTS AND METHODS: Thirty patients with relapsed neuroblastoma were treated in groups of six with escalating doses of 3 to 18 mCi/kg of 131I-MIBG. After rapid escalation in the first three patients treated at 3 to 6 mCi/kg, treatment was escalated in 3-mCi/kg increments from 9 to 18 mCi/kg. Autologous tumor-free bone marrow was cryopreserved in all patients receiving 12 mCi/kg and more. Toxicity and response were assessed. RESULTS: Eighty percent of patients who received 12 mC/kg or more experienced grade 4 thrombocytopenia and/or neutropenia. Dose-limiting hematologic toxicity was reached at 15 mCi/kg, at which level two of five assessable patients required bone marrow reinfusion for absolute neutrophil count (ANC) of less than 200/microL for more than 2 weeks, and four of nine at the 18-mCi/kg level. Prolonged thrombocytopenia was common, with failure to become platelet-transfusion independent in nine patients. One patient with extensive prior treatment developed secondary leukemia and three became hypothyroid. Responses were seen in 37% of patients, with one complete response (CR), 10 partial response (PR), three mixed response, 10 stable disease, and six progressive disease. The minimum dose of 131I- MIBG for 10 of the 11 responders was 12 mCi/kg. CONCLUSION: Treatment with 131I-MIBG has mainly hematologic toxicity, which can be abrogated with bone marrow rescue. The high response rate in refractory disease suggests that this agent may be useful in combination with myeloablative chemotherapy and autologous stem-cell rescue to improve outcome in advanced neuroblastoma.

This article has been cited by other articles:

				W. J. G. Oyen, L. Bodei, F. Giammarile, H. R. Maecke, J. Tennvall, M. Luster, and B. Brans Targeted therapy in nuclear medicine current status and future prospects Ann. Onc., November 1, 2007; 18(11): 1782 - 1792. [Abstract] [Full Text] [PDF]

				R. J. Mairs, S. C. Ross, A. G. McCluskey, and M. Boyd A Transfectant Mosaic Xenograft Model for Evaluation of Targeted Radiotherapy in Combination with Gene Therapy In Vivo J. Nucl. Med., September 1, 2007; 48(9): 1519 - 1526. [Abstract] [Full Text] [PDF]

				K. K. Matthay, G. Yanik, J. Messina, A. Quach, J. Huberty, S.-C. Cheng, J. Veatch, R. Goldsby, P. Brophy, L. S. Kersun, et al. Phase II Study on the Effect of Disease Sites, Age, and Prior Therapy on Response to Iodine-131-Metaiodobenzylguanidine Therapy in Refractory Neuroblastoma J. Clin. Oncol., March 20, 2007; 25(9): 1054 - 1060. [Abstract] [Full Text] [PDF]

				M. Boyd, S. C. Ross, J. Dorrens, N. E. Fullerton, K. W. Tan, M. R. Zalutsky, and R. J. Mairs Radiation-Induced Biologic Bystander Effect Elicited In Vitro by Targeted Radiopharmaceuticals Labeled with {alpha}-, {beta}-, and Auger Electron-Emitting Radionuclides J. Nucl. Med., June 1, 2006; 47(6): 1007 - 1015. [Abstract] [Full Text] [PDF]

				K. K. Matthay, J. C. Tan, J. G. Villablanca, G. A. Yanik, J. Veatch, B. Franc, E. Twomey, B. Horn, C. P. Reynolds, S. Groshen, et al. Phase I Dose Escalation of Iodine-131-Metaiodobenzylguanidine With Myeloablative Chemotherapy and Autologous Stem-Cell Transplantation in Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Consortium Study J. Clin. Oncol., January 20, 2006; 24(3): 500 - 506. [Abstract] [Full Text] [PDF]

				V. Kersemans, B. Cornelissen, K. Bacher, K. Kersemans, H. Thierens, R. A. Dierckx, B. De Spiegeleer, G. Slegers, and J. Mertens In Vivo Evaluation and Dosimetry of 123I-2-Iodo-D-Phenylalanine, a New Potential Tumor-Specific Tracer for SPECT, in an R1M Rhabdomyosarcoma Athymic Mouse Model J. Nucl. Med., December 1, 2005; 46(12): 2104 - 2111. [Abstract] [Full Text] [PDF]

				D. P. Lee, J. M. Skolnik, and P. C. Adamson Pediatric Phase I Trials in Oncology: An Analysis of Study Conduct Efficiency J. Clin. Oncol., November 20, 2005; 23(33): 8431 - 8441. [Abstract] [Full Text] [PDF]

				M. G. E. H. Lam, C. J. M. Lips, P. L. Jager, R. P. F. Dullaart, E. G. W. M. Lentjes, P. P. van Rijk, and J. M. H. de Klerk Repeated [131I]Metaiodobenzylguanidine Therapy in Two Patients with Malignant Pheochromocytoma J. Clin. Endocrinol. Metab., October 1, 2005; 90(10): 5888 - 5895. [Abstract] [Full Text] [PDF]

				F. D. Pashankar, M. S. O'Dorisio, and Y. Menda MIBG and Somatostatin Receptor Analogs in Children: Current Concepts on Diagnostic and Therapeutic Use J. Nucl. Med., January 1, 2005; 46(1_suppl): 55S - 61S. [Abstract] [Full Text] [PDF]

				G. Eisenhofer, S. R Bornstein, F. M Brouwers, N.-K. V Cheung, P. L Dahia, R. R de Krijger, T. J Giordano, L. A Greene, D. S Goldstein, H. Lehnert, et al. Malignant pheochromocytoma: current status and initiatives for future progress Endocr. Relat. Cancer, September 1, 2004; 11(3): 423 - 436. [Abstract] [Full Text] [PDF]

				B. H. Kushner Neuroblastoma: A Disease Requiring a Multitude of Imaging Studies J. Nucl. Med., July 1, 2004; 45(7): 1172 - 1188. [Abstract] [Full Text] [PDF]

				S. G. DuBois, J. Messina, J. M. Maris, J. Huberty, D. V. Glidden, J. Veatch, M. Charron, R. Hawkins, and K. K. Matthay Hematologic Toxicity of High-Dose Iodine-131-Metaiodobenzylguanidine Therapy for Advanced Neuroblastoma J. Clin. Oncol., June 15, 2004; 22(12): 2452 - 2460. [Abstract] [Full Text] [PDF]

				P. Brophy, C. Schmus, and L. Balistreri Meeting the Nursing Challenges Intreating Children with 131 I-MIBG Journal of Pediatric Oncology Nursing, January 1, 2004; 21(1): 9 - 15. [Abstract] [PDF]

				J. L. Weinstein, H. M. Katzenstein, and S. L. Cohn Advances in the Diagnosis and Treatment of Neuroblastoma Oncologist, June 1, 2003; 8(3): 278 - 292. [Abstract] [Full Text] [PDF]

				B. H. Kushner, S. D.J. Yeh, K. Kramer, S. M. Larson, and N.-K. V. Cheung Impact of Metaiodobenzylguanidine Scintigraphy on Assessing Response of High-Risk Neuroblastoma to Dose-Intensive Induction Chemotherapy J. Clin. Oncol., March 15, 2003; 21(6): 1082 - 1086. [Abstract] [Full Text] [PDF]

				G. A. Yanik, J. E. Levine, K. K. Matthay, J. C. Sisson, B. L. Shulkin, B. Shapiro, D. Hubers, S. Spalding, T. Braun, J. L.M. Ferrara, et al. Pilot Study of Iodine-131-Metaiodobenzylguanidine in Combination With Myeloablative Chemotherapy and Autologous Stem-Cell Support for the Treatment of Neuroblastoma J. Clin. Oncol., April 15, 2002; 20(8): 2142 - 2149. [Abstract] [Full Text] [PDF]

				K. K. Matthay, C. Panina, J. Huberty, D. Price, D. V. Glidden, H. R. Tang, R. A. Hawkins, J. Veatch, and B. Hasegawa Correlation of Tumor and Whole-Body Dosimetry with Tumor Response and Toxicity in Refractory Neuroblastoma Treated with 131I-MIBG J. Nucl. Med., November 1, 2001; 42(11): 1713 - 1721. [Abstract] [Full Text] [PDF]

				B. H. Kushner, S. Wolden, M. P. LaQuaglia, K. Kramer, D. Verbel, G. Heller, and N.-K. V. Cheung Hyperfractionated Low-Dose Radiotherapy for High-Risk Neuroblastoma After Intensive Chemotherapy and Surgery J. Clin. Oncol., June 1, 2001; 19(11): 2821 - 2828. [Abstract] [Full Text] [PDF]

				H. R. Tang, A. J. Da Silva, K. K. Matthay, D. C. Price, J. P. Huberty, R. A. Hawkins, and B. H. Hasegawa Neuroblastoma Imaging Using a Combined CT Scanner-Scintillation Camera and 131I-MIBG J. Nucl. Med., February 1, 2001; 42(2): 237 - 247. [Abstract] [Full Text]